Table 1.
Model Results
| CRC Stage A+B Cases/100K Screened | CRC Stage C Cases/100K Screened | CRC Stage D Cases/100K Screened | Cost/Screened Individual | Quality-adjusted Life Years/Screened Individual | Life Years/Screened Individual | Incremental Cost-Effectiveness Ratio (ICER) | ||
|---|---|---|---|---|---|---|---|---|
| Screened at 30 Years Old | ||||||||
| Population Screening | Base Case | 1,992 | 1,526 | 898 | $2,147 | 25.504 | 25.507 | |
| 95% Credible Range (CR) | (1,704 to 2,269) | (1,272 to 1,780) | (733 to 1,086) | ($1,988 to $2,311) | (25.498 to 25.509) | (25.502 to 25.512) | ||
| Family History-Based Testing | Base Case | 2,008 | 1,535 | 911 | $1,913 | 25.502 | 25.506 | |
| 95% CR | (1,719 to 2,285) | (1,281 to 1,790) | (743 to 1,100) | ($1,759 to $2,074) | (25.496 to 25.508) | (25.501 to 25.511) | ||
| Incremental | Base Case | −20 | −12 | −16 | $246 | 0.002 | 0.002 | $132,151 |
| 95% CR | (−34 to −8) | (−23 to −2) | (−26 to −8) | ($203 to $292) | (0.001 to 0.003) | (0.001 to 0.003) | ($86,867 to $208,010) | |
| Screened at 50 Years Old | ||||||||
| Population Screening | Base Case | 1,908 | 1,462 | 862 | $3,073 | 19.711 | 19.716 | |
| 95% CR | (1,629 to 2,174) | (1,223 to 1,723) | (696 to 1,051) | ($2,834 to $3,332) | (19.703 to 19.718) | (19.709 to 19.723) | ||
| Family History-Based Testing | Base Case | 1,921 | 1,469 | 872 | $2,860 | 19.710 | 19.715 | |
| 95% CR | (1,639 to 2,190) | (1,230 to 1,731) | (707 to 1,060) | ($2,626 to $3,127) | (19.701 to 19.717) | (19.708 to 19.722) | ||
| Incremental | Base Case | −17 | −10 | −13 | $226 | 0.002 | 0.002 | $140,371 |
| 95% CR | (−27 to −7) | (−19 to −2) | (−21 to −7) | ($182 to $267) | (0.001 to 0.002) | (0.001 to 0.002) | ($88,974 to $221,820) | |